Results 41 to 50 of about 110,630 (313)

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers [PDF]

Drugs, 2018
The mitogen activated protein kinase/extracellular signal-related kinase (MAPK/ERK) signaling pathway serves an integral role in growth, proliferation, differentiation, migration, and survival of all mammalian cells. Aberrant signaling of this pathway is often observed in several types of hematologic and solid malignancies.
Jaquelyn N. Sanchez, Ton Wang, Mark S. Cohen   +2 more
openaire   +2 more sources

Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy [PDF]

, 2014
Phosphatase and tensin homolog (PTEN) loss is associated with genomic instability. APE1 is a key player in DNA base excision repair (BER) and an emerging drug target in cancer.
Seedhouse, C, Seedhouse, Claire, Simeonov, Anton, Grabowska, Anna, Jewell, Rosalyn, Nsengimana, J, Ball, G, Abbotts, Rachel, Ball, Graham, Elliott, Faye, Walker, Christy, Wilson III, David M, Wilson III, DM, Patel, Poulam M, Elliott, F, Jadhav, Ajit, Grabowska, A, Laye, J, Simeonov, A, Maloney, DJ, Wilson, DM, Maloney, David J, Madhusudan, Srinivasan, Abbotts, R, Nsengimana, J�r�mie, Jadhav, A, Jewell, R, Madhusudan, S, Walker, C, Patel, PM, Newton-Bishop, J, Laye, Jon, Newton-Bishop, Julia   +32 more
core   +1 more source

Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas [PDF]

, 2016
The aim of our study was to inhibit BRAF kinase expression and investigate its effect on cellular functions in thyroid carcinomas. 8505C (BRAF V600E/V600E) undifferentiated thyroid carcinoma cell line and B-CPAP (BRAF V600E/V600E) papillary thyroid ...
Ariana, Armin, Salajegheh, Ali, Rahman, Md Atiqur, Lam, Alfred King-Yin, Lam, Alfred, Smith, Robert Anthony, Rahman, Md. Atiqur, Smith, Robert A.   +7 more
core   +1 more source

BRAF inhibitors: From the laboratory to clinical trials [PDF]

, 2014
BRAF is one of the most commonly mutated proto-oncogenes and plays a significant role in the development of numerous cancers of high clinical impact. Due to the commonality of BRAF mutations, a number of BRAF inhibitors have been developed as tools in ...
Ariana, Armin, Rahman, M.A., Lam, AK-Y, Salajegheh, A, Lam, Alfred, Rahman, MA, Smith, RA, Smith, Robert, Salajegheh, A., Smith, R.A., Lam, A.K.-Y., Rahman, Md. Atiqur   +11 more
core   +1 more source

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [PDF]

New England Journal of Medicine, 2014
Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or ...
G. V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. De Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. J. Grob, V. Chiarion Sileni, C. Lebbe, M. Mandalà, M. Millward, A. Arance, I. Bondarenko, J. B. A. G. Haanen, J. Hansson, J. Utikal, V. Ferraresi, N. Kovalenko, P. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, D. J. Demarini, J. G. Irani, M. Casey, D. Ouellet, A. . Martin, N. Le, K. Patel, K. Flaherty   +34 more
openaire   +3 more sources

Clinicopathological relevance of BRAF mutations in human cancer [PDF]

, 2013
Summary: BRAF represents one of the most frequently mutated protein kinase genes in human tumours. The mutation is commonly tested in pathology practice.
Ariana, Armin, Salajegheh, Ali, Lam, Alfred King-Yin, Lam, Alfred, Pakneshan, Sahar, Smith, Robert, Smith, Robert Anthony, Smith, Robert A.   +7 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Re‐Irradiation in Pediatric Diffuse Midline Glioma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with recurrent diffuse midline gliomas (DMGs) have limited therapeutic options at recurrence. Re‐irradiation (RT2) may be used at progression, but with uncertainty about the benefit. Methods We conducted a multi‐institutional retrospective study of children aged < 18 with DMG treated at three centers (Toronto, Canada ...
Ajay Thomas Alex, Sean P. Hassan, Helen Benghiat, Liam Herbert, Jennifer Adamski, Shivani Bailey, Claire Esler, Louise Brookes, Molly Bamber, Grace Koudou, Karen Waite, Julie Bennett, Anirban Das, Derek S. Tsang   +13 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Pharmacological targeted therapy of Braf mutant melanoma (Braf and MEK inhibitors) [PDF]

, 2018
The Thesis is based upon the approach of Pharmacological targeted therapy of Braf mutant melanoma with both Braf and MEK inhibitors. The BRAF inhibitors, Vemurafenib (Zelboraf) and Dabrafenib (Tafinlar), targets the BRAF kinase directly resulting in the ...
Abraham Waldu, Saim
core